A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer von Kruczek, K, Ratterman, M, Tolzien, K, Sulo, S, Lestingi, T M, Nabhan, C

Volltext

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer von Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H

Volltext

Safety and activity of lenalidomide (LEN) in elderly patients (pts) with chemotherapy-naive, castration-resistant prostate cancer (CRPC) von Lestingi, T. M., Tolzien, K., Kelby, S. K., Nabhan, C.

Volltext

Maintenance GM-CSF in patients with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy von Bitran, J. D., Tolzien, K., Lestingi, T. M., Nabhan, C.

Volltext

A pilot study investigating maintenance sargramostim in patients with androgen-independent prostate cancer (AIPC) who have maximized their response to chemotherapy: preliminary res... von Bitran, J. D., Tolzien, K., Lestingi, T. M., Nabhan, C.

Volltext

Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC) von Nabhan, C., Tolzien, K., Lestingi, T. M., Galvez, A., Bitran, J. D.

Volltext

A phase II study with single agent erlotinib in chemotherapy-naïve androgen independent prostate cancer (AIPC) von Lestingi, T. M., Tolzien, K., Galvez, A., Kelby, S., Bitran, J. D., Nabhan, C.

Volltext

Erlotinib has activity in androgen-independent prostate cancer (AIPC) patients who are chemotherapy-naive: A phase II trial von Nabhan, C., Tolzien, K., Newman, S., Kelby, S., Lestingi, T., Galvez, A., Bitran, J. D.

Volltext

Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial von Nabhan, Chadi, Lestingi, Timothy M, Galvez, Angel, Tolzien, Kathy, Kelby, Susan K, Tsarwhas, Dean, Newman, Steven, Bitran, Jacob D

Volltext

Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study von Nabhan, Chadi, Patel, Anand, Villines, Dana, Tolzien, Kathy, Kelby, Susan K, Lestingi, Timothy M

Volltext

Effect of lenalidomide (LEN) on biochemical responses and clinical benefit (CB) as a single agent in chemotherapy-naive castration-resistant prostate cancer (CRPC) von Nabhan, Chadi, Patel, Anand, Villines, Dana, Tolzien, Kathy, Kelby, Susan K., Lestingi, Timothy M.

Volltext